Lung Cancer | Specialty

The lung cancer condition center is a comprehensive resource for clinical news and expert insights on lung cancer. Read more at OncLive.

Dr Liu on the Ongoing Investigation of Zidesamtinib in ROS1+ Tumors

May 2nd 2024

Stephen V. Liu, MD, discusses the potential benefits and ongoing investigation of zidesamtinib for patients with ROS1-positive tumors.

Fox Chase Cancer Center Researchers Show Estrogen Metabolites Contribute to Development of Lung Cancer Among People Who Never Smoked

May 2nd 2024

Fox Chase Cancer Center researchers showed that estrogen is metabolized in lungs, contributing to the development of lung cancer in never smokers.

DESTINY-Lung04: First-Line Trastuzumab Deruxtecan in HER2-Mutated NSCLC

May 1st 2024

Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2 NSCLC.

The Role of Trastuzumab Deruxtecan in HER2-Mutated NSCLC

May 1st 2024

Experts on HER2 NSCLC discuss the patient populations in which they’d utilize trastuzumab deruxtecan and share their clinical experiences with the therapy.

Glecirasib Generates Durable Responses in Pretreated Advanced KRAS G12C+ NSCLC

April 30th 2024

Glecirasib elicited responses and demonstrated a manageable safety profile in patients with pretreated advanced NSCLC harboring KRAS G12C mutations.

Dr Ahluwalia on Advancements in the Management of Brain Metastases

April 30th 2024

Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses how advancements in precision medicine have improved outcomes for patients with brain metastases.

Differences Between DNA and RNA Testing for NRG1

April 29th 2024

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses differences between DNA and RNA fusions for detecting NRG1 fusions.

Prevalence of NRG1 Fusions in Lung Cancer

April 29th 2024

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses the prevalence of NRG1 fusions in lung cancer.

Frontline Amivantamab Plus Chemo Receives Positive EU CHMP Opinion for EGFR Exon 20 Insertion+ NSCLC

April 26th 2024

Frontline amivantamab with chemotherapy has been recommended for approval by the CHMP in EGFR exon 20 insertion+ non–small cell lung cancer.

Dr Singh on Unmet Medical Needs in Lung Cancer Treatment

April 25th 2024

Raj Singh, MD, discusses unmet medical needs in the treatment of patients with lung cancer.

DESTINY-Lung01 & DESTINY-Lung02: T-DXd in Metastatic HER2-Mutated NSCLC

April 24th 2024

Lyudmila A. Bazhenova, MD, and D. Ross Camidge, MD, PhD, review the DESTINY-Lung01 and DESTINY-Lung02 trials, and the panel provides its impressions of the data.

Role of ADCs in HER2-Mutated NSCLC

April 24th 2024

The panel discusses the role of antibody-drug conjugates (ADCs) and the treatment of patients with HER2 non–small cell lung cancer.

Dr Simon on the ALK Inhibitor Selection Process in ALK+ NSCLC

April 24th 2024

George R Simon, MD, FACP, FCCP on selecting ALK inhibitors in ALK-positive non–small cell lung cancer.

Singh Discusses the Shift Toward Stereotactic Radiation Therapy in Lung Cancer

April 23rd 2024

Raj Singh, MD, discusses the use of stereotactic body radiation therapy and stereotactic radiosurgery in the treatment of patients with lung cancer.

Dr Eric Singhi Navigates Advocacy, Mentorship, and More in NSCLC Management

April 23rd 2024

Eric K. Singhe, MD, of The University of Texas MD Anderson Cancer Center, discusses the journey of non–smell cell lung cancer treatment through mentorship, advocacy, and more.

Tislelizumab Receives EU Approval in 3 Indications for First- and Second-Line NSCLC

April 23rd 2024

Tislelizumab has been approved in Europe across 3 indications in the first and second line for select patients with non–small cell lung cancer.

Health Canada Green Lights Subcutaneous Atezolizumab for Lung, Breast, and Liver Cancer

April 23rd 2024

Health Canada has approved subcutaneous atezolizumab for use in patients with lung cancer, breast cancer, and hepatocellular carcinoma.

FAK Inhibition Emerges as a Potential Complementary Treatment Pathway

April 22nd 2024

Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens.

Dr Saxena on Shifts in Treatment With Targeted and Immune Therapies in NSCLC

April 19th 2024

Ashish Saxena, MD, PhD, discusses recent shifts in treatment with the use of targeted and immune therapies in non–small cell lung cancer.

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC

April 18th 2024

The FDA has approved alectinib as adjuvant treatment in select patients with ALK-positive non–small cell lung cancer.